Sanofi-Aventis Expands Rimonabant Diabetes Program With Multiple Trials

Sanofi-Aventis is expanding its Zimulti (rimonabant) diabetes program after clinical study results showed the drug's effectiveness in reducing HbA1c is comparable to oral anti-diabetics